Analytical Data
-
Gene name
E2F1
- Application
-
Alternative Names
E2F1；RBBP3；Transcription factor E2F1
-
Species
Human
-
Source
E. coli
-
Tag
N-terminal His-Tag
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q01094
-
Expression Region
1-437aa
-
AA Sequence
MALAGAPAGGPCAPALEALLGAGALRLLDSSQIVIISAAQDASAPPAPTGPAAP AAGPCDPDLLLFATPQAPRPTPSAPRPALGRPPVKRRLDLETDHQYLAESSGPA RGRGRHPGKGVKSPGEKSRYETSLNLTTKRFLELLSHSADGVVDLNWAAEVLKV QKRRIYDITNVLEGIQLIAKKSKNHIQWLGSHTTVGVGGRLEGLTQDLRQLQES EQQLDHLMNICTTQLRLLSEDTDSQRLAYVTCQDLRSIADPAEQMVMVIKAPPE TQLQAVDSSENFQISLKSKQGPIDVFLCPEETVGGISPGKTPSQEVTSEEENRA TDSATIVSPPPSSPPSSLTTDPSQSLLSLEQEPLLSRMGSLRAPVDEDRLSPLV AADSLLEHVREDFSGLLPEEFISLSPPHEALDYHFGLEEGEGIRDLFDCDFGDL TPLDF
-
Molecular Weight
53.0kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Identification
Protein Description
E2F1 is a crucial transcription factor involved in regulating gene expression during the cell cycle, particularly in the transition from the G1 to S phase. Research has shown that E2F1 not only drives cell proliferation but also plays significant roles in apoptosis and DNA damage response, making it a critical player in cancer biology. The dysregulation of E2F1 activity is associated with various cancers, as overexpression can lead to uncontrolled cell growth, while insufficient activity may impede normal cell cycle progression. Given its dual role in promoting cell survival and facilitating cell death, E2F1 presents a complex target for therapeutic intervention. Studies have focused on understanding the molecular mechanisms that govern E2F1's activity, including post-translational modifications, interactions with other proteins, and its transcriptional regulatory networks. The potential for E2F1-based therapies is being actively explored, with the aim of harnessing its properties for cancer treatment, particularly in tumors where E2F1 is aberrantly expressed. Overall, the research surrounding E2F1 and its recombinant proteins is pivotal for developing novel strategies to manage cancer and exploit its regulatory pathways for therapeutic benefits.
